Anti-PD-1/PD-L1 with bevacizumab and low-dose cyclophosphamide for metastatic NSCLC and cutaneous melanoma after prior checkpoint therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2 interventional trial testing a combination of anti-PD-1/PD-L1 antibodies with bevacizumab and metronomic (continuous low-dose) cyclophosphamide in patients with metastatic non-small cell lung cancer or cutaneous melanoma who previously received immune checkpoint blockade. The regimen aims to overcome acquired resistance to PD-1/PD-L1 therapy by normalizing tumor vasculature (bevacizumab) and altering the tumor immune environment through low-dose cyclophosphamide effects on regulatory and myeloid cells. Key outcomes include progression-free survival, overall survival, objective response rate, and safety. The trial is being conducted at EuroCityClinic in Saint Petersburg, Russia, with academic collaboration from First Pavlov State Medical University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Provide written informed consent
* Age ≥ 18 years
* Histologically confirmed diagnosis of NSCLC and cutaneous melanoma with distant metastases.
* No mutations in the EGFR gene, ALK, ROS1, RET gene translocations (in case of NSCLC).
* For NSCLC: the individuals had previously received anti-PD-(L)1 antibodies in combination with platinum-containing chemotherapy either in the first line or sequentially in the first and second lines for the treatment of metastatic disease.
* For NSCLC: the individuals had previously received anti-PD-(L)1 antibodies for \>6 months and experienced disease progression.
* For cutaneous melanoma: the individuals had previously received anti-PD-1 antibodies either in combination with or without anti-CTLA4 therapy for metastatic disease. If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.
* For cutaneous melanoma: the patient has previously received anti-PD-1 antibodies with or without anti-CTLA4 therapy for metastatic disease for \>6 months and experienced disease progression

Exclusion Criteria:

* Presence of clinically significant cardiovascular disease: severe or unstable ischemic heart disease, history of myocardial infarction, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias.
* Stroke and/or transient ischemic attack within 6 months prior to screening;
* Uncontrolled hypertension
* History of previous malignancies except non-melanoma skin cancers, or in situ cervical or breast cancer unless a complete remission was achieved at least 2 years prior to randomization AND no additional therapy is required during the study period. Patients having hepatic involvement of cancer should be excluded as per investigator assessment.
* Patients with CNS metastases are eligible only if the metastases are adequately treated.
* Absolute neutrophil count (ANC) \<1.5×109/L, platelet count \<100×109/L, or hemoglobin \<9.0 g/dL.
* Serum total bilirubin \>1.5 × the upper limit of normal (ULN). Participants with Gilbert syndrome, bilirubin \<2 X ULN, and normal AST/ALT are eligible;
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × ULN;
* Serum creatinine \>1.5 × ULN.
* History of a thromboembolic event
* Presence of any allergic reactions to components of the study drugs
* Concomitant medications with a known risk of causing QT prolongation and/or Torsades de Pointes.
* Any parallel anti-cancer systemic therapy, radiation therapy
* Women who are pregnant or lactating;
* Presence of unresolved adverse events of grade 2 or higher toxicity, according to CTCAE v5.0 criteria, from prior therapy (except for alopecia or neurotoxicity grade≤2).
* Any other serious or uncontrolled medical disorder, active infection, physical examination finding, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a patient's ability to comply with the study requirements, substantially increase risk to the patient, or impact the interpretability of study results.

Where it's running

• EuroCityClinic LLC
  Saint Petersburg, Sankt-Peterburg, Russia Recruiting

Study contacts

• Principal investigator: Sergey V. Orlov, Professor — EuroCityClinic LLC
• Study coordinator: Sergey V. Orlov, Professor
• Email: orloff-sv@mail.ru
• Phone: +79811957915

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining pembrolizumab, bevacizumab, and cyclophosphamide for treating ovarian cancer with minimal residual disease

  This study is testing a new combination of three drugs to see if it can help women with high-grade ovarian cancer who have very little disease left after treatment live longer without their cancer getting worse.

  Recruiting Phase 2 M.D. Anderson Cancer Center · New York, New York and 1 other locations · NCT06083844

• Combining cyclophosphamide, sorafenib, bevacizumab, and atezolizumab for children and young adults with relapsed solid tumors

  This will test whether giving atezolizumab and bevacizumab every three weeks together with daily cyclophosphamide and dose‑adjusted sorafenib is safe and can shrink relapsed or hard‑to‑treat solid tumors in children and young adults, including fibrolamellar carcinoma.

  Recruiting Phase 1/2 St. Jude Children's Research Hospital · Germantown, Tennessee and 1 other locations · NCT05468359

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.